Novelion Therapeutics Inc.

Equities

NVLNF

CA67001K2020

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-4.49%	-0.54%

2022	Novelion Therapeutics Inc. Announces Final Cash Distribution, Payable on or About March 31, 2022	CI
2020	Novelion Therapeutics Inc. Announces Management Changes	CI

Novelion Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019

May 07, 2019 at 05:12 pm EDT

Novelion Therapeutics Inc. announced earnings results for the first quarter ended March 31, 2019. For the first quarter, the company announced sales was USD 32.200 million compared to USD 27.484 million a year ago. Operating loss was USD 15.988 million compared to USD 21.476 million a year ago. Net loss was USD 31.847 million compared to USD 32.828 million a year ago. Basic loss per share was USD 1.67 compared to USD 1.76 a year ago.

Latest news about Novelion Therapeutics Inc.

Novelion Therapeutics Inc. Announces Final Cash Distribution, Payable on or About March 31, 2022	22-03-28	CI
Novelion Therapeutics Inc. Announces Management Changes	20-01-16	CI
Novelion Therapeutics Inc. Announces Management Changes	20-01-03	CI
Declaration of Voting Results by Novelion Therapeutics Inc.	19-11-05	CI
Declaration of Voting Results by Novelion Therapeutics Inc.	19-11-05	CI
Novelion Therapeutics Inc.(OTCPK:NVLN.F) dropped from NASDAQ Composite Index	19-10-08	CI
Novelion Therapeutics Provides Information to Shareholders	19-10-04	CI
Novelion Therapeutics Provides Information to Shareholders	19-10-04	CI
Novelion Therapeutics Inc. Provides Information to the Shareholders	19-10-03	CI
Novelion Therapeutics Inc. Provides Information to the Shareholders	19-10-03	CI
Novelion Therapeutics Inc. Elects Michael D. Price to Serve as a Director	19-10-03	CI
Novelion Therapeutics Inc. Announces Management Changes	19-09-25	CI
Novelion Therapeutics Provides Information to Shareholders	19-09-20	CI
Novelion Therapeutics Responds to Whitefort Capital Petition	19-06-24	CI
Whitefort Capital Files a Petition Against Novelion Therapeutics	19-06-20	CI
Novelion Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-07	CI
Novelion Therapeutics Inc. Provides the Earnings Guidance for the Year 2019	19-05-07	CI
Whitefort Capital Discloses its Views on Novelion Therapeutics	19-04-02	CI
Novelion Therapeutics Inc. Auditor Raises 'Going Concern' Doubt	19-03-14	CI
Novelion Therapeutics Inc. Provides Revenue Guidance for the Year 2019	19-03-14	CI
Novelion Therapeutics Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2018	19-03-14	CI
Healthcare Value Urges Novelion To Explore Strategic Alternatives	18-12-04	CI
Novelion Is Considering Multiple Strategic Alternatives	18-12-04	CI
Healthcare Value Pushes Novelion Therapeutics to Explore Strategic Alternatives	18-12-03	CI
Novelion Therapeutics Inc. Announces Executive Changes	18-11-20	CI

Chart Novelion Therapeutics Inc.

Duration

Period

More charts

Company Profile

Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company's portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.

Sector

More about the company